ADC Therapeutics (NYSE:ADCT) Posts Earnings Results, Beats Expectations By $0.23 EPS

ADC Therapeutics (NYSE:ADCT) released its quarterly earnings data on Tuesday. The company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.23, FiscalAI reports. The firm had revenue of $23.06 million for the quarter, compared to analyst estimates of $22.29 million.

Here are the key takeaways from ADC Therapeutics’ conference call:

• The company has refocused on ZYNLONTA lifecycle management, cut operating costs by ~50%, upgraded leadership, and strengthened the balance sheet (cash $261M) with a stated runway into 2028.
• Key clinical catalysts ahead — management expects LOTIS-5 top-line PFS data in Q2 2026, and LOTIS-7 showed a 90% ORR and 78% CR in 49 evaluable patients with enrollment expanded to ~100.
• Commercially, 2025 net product revenues were $73.6M (Q4 $22.3M) with volumes broadly flat and an estimated ~10% share in third-line DLBCL; management expects stability until label expansion.
• Despite reduced expenses and a narrower GAAP loss, the company reported a full-year net loss of $142.6M and future upside depends on regulatory approvals, compendia inclusion and competition from bispecifics, posing execution risk.

ADC Therapeutics Trading Up 13.4%

Shares of ADCT stock opened at $4.80 on Wednesday. The firm has a fifty day simple moving average of $3.89 and a 200-day simple moving average of $3.87. The company has a market capitalization of $594.00 million, a PE ratio of -3.31 and a beta of 1.92. ADC Therapeutics has a twelve month low of $1.05 and a twelve month high of $4.95.

Analyst Ratings Changes

A number of research firms have issued reports on ADCT. Wall Street Zen raised ADC Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th. Guggenheim restated a “buy” rating and issued a $10.00 price objective on shares of ADC Therapeutics in a report on Wednesday, November 12th. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $5.00 price objective on shares of ADC Therapeutics in a research note on Wednesday, December 3rd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of ADC Therapeutics in a research report on Wednesday, January 21st. Three equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, ADC Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $7.33.

Key Headlines Impacting ADC Therapeutics

Here are the key news stories impacting ADC Therapeutics this week:

• Positive Sentiment: Q4 financial beat — ADC reported Q4 EPS of ($0.09) vs. consensus (~($0.32)) and revenue roughly $23.1M; company disclosed Q4 net product revenue ≈ $22.3M and FY product revenue ≈ $73.6M, which underpins the upside reaction. PR Newswire: Q4 & FY 2025 Results
• Positive Sentiment: Cash runway and financing flexibility — ADC reported $261.3M cash as of 12/31/25 and announced an amendment to its HealthCare Royalty financing agreement that management said increases strategic flexibility, lowering near‑term dilution/funding risk. PR Newswire: Cash & Financing
• Positive Sentiment: Clear near‑term clinical catalysts — management reiterated LOTIS‑5 Phase 3 topline is expected in Q2 2026, with full readouts for LOTIS‑5 and LOTIS‑7 by year‑end 2026; positive results would be materially value‑creating. PR Newswire: Operational Update
• Positive Sentiment: Commercial ambition for ZYNLONTA — company outlined a $600M–$1B peak revenue target for ZYNLONTA and is advancing label/indication efforts, supporting upside to current sales assumptions if trials/launch execution succeed. Seeking Alpha: Peak Revenue Target
• Positive Sentiment: Market reaction — coverage notes the stock has cleared a 52‑week high after the earnings/updates, reflecting investor appetite for the combination of beat + pipeline clarity. AmericanBankingNews: 52‑Week High
• Neutral Sentiment: Earnings call and transcript available — management discussed commercial execution and development timelines on the call; useful detail for modeling but no formal updated revenue guidance was issued. Seeking Alpha: Call Transcript
• Negative Sentiment: Binary clinical risk — the LOTIS‑5 topline in Q2 is a near‑term binary event: a disappointing result would likely drive sharp downside given reliance on future label expansion. PR Newswire: LOTIS‑5 Timeline
• Negative Sentiment: Company remains loss‑making and analysts still model negative EPS for the year, so valuation depends on pipeline success and commercial execution rather than current profitability. Zacks: Q4 Loss & Estimates

Hedge Funds Weigh In On ADC Therapeutics

A number of institutional investors have recently added to or reduced their stakes in ADCT. Charles Schwab Investment Management Inc. boosted its position in ADC Therapeutics by 16.8% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 212,668 shares of the company’s stock valued at $751,000 after buying an additional 30,656 shares during the last quarter. AQR Capital Management LLC increased its position in shares of ADC Therapeutics by 42.2% during the fourth quarter. AQR Capital Management LLC now owns 206,576 shares of the company’s stock worth $729,000 after acquiring an additional 61,324 shares during the last quarter. Barclays PLC lifted its stake in shares of ADC Therapeutics by 23.7% in the fourth quarter. Barclays PLC now owns 161,386 shares of the company’s stock worth $570,000 after acquiring an additional 30,926 shares in the last quarter. State of Wisconsin Investment Board acquired a new position in shares of ADC Therapeutics in the fourth quarter worth about $400,000. Finally, Cantor Fitzgerald L. P. purchased a new position in ADC Therapeutics in the fourth quarter valued at about $353,000. Institutional investors and hedge funds own 41.10% of the company’s stock.

ADC Therapeutics Company Profile

ADC Therapeutics SA is a clinical-stage biopharmaceutical company focused on the discovery and development of highly targeted antibody-drug conjugates (ADCs) designed to treat hematological malignancies such as non-Hodgkin lymphoma and acute myeloid leukemia. By marrying the specificity of monoclonal antibodies with potent cytotoxic payloads, the company aims to maximize tumor cell eradication while limiting off-target toxicity.

At the core of ADC Therapeutics’ portfolio is loncastuximab tesirine-lpyl, a CD19-directed ADC that received accelerated approval from the U.S.